Stocktoria
ImmunityBio, Inc. IBRX
ImmunityBio, Inc. (IBRX) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $113.3M at a -310.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-21 | BTIG | Buy (reit) |
| 2026-05-20 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-05 | D. Boral Capital | Buy (main) |
| 2026-04-21 | D. Boral Capital | Buy (main) |
| 2026-04-08 | D. Boral Capital | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
FAQ
Is IBRX financially healthy?
ImmunityBio, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does IBRX pay a dividend?
No, ImmunityBio, Inc. does not currently pay a dividend.
How profitable is IBRX?
In FY2025, ImmunityBio, Inc. had a net margin of -310.2%.
What is the analyst price target for IBRX?
The average Wall-Street price target for ImmunityBio, Inc. is $13.00, about 68.0% above the recent price, from 3 analysts.
Is IBRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ImmunityBio, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.